This modeling strategy is rationalized by the observation that, in contrast to C3/EZB DLBCL where BCL2 is typically affected by structural variants, BCL2 is typically amplified in C5/MCD (2, 3, 28). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.